Medicaid’s ‘GENEROUS’ pricing may not save states money

Taking stock of the drug industry, from the lab to the medicine chest

November 10, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

STAT+ | Medicaid's 'GENEROUS' pricing may not save states money In biotech news today: Medicaid's 'GENEROUS' plan may not save states money. Also, the Metsera love triangle ends in a fierce bidding war By Meghana Keshavan STAT+ | Merck's pill to reduce cholesterol on top of statins matches results from injectables Merck's enlicitide pill lowered LDL cholesterol by up to 60%, matching injectables like Repatha and offering an easier option for patients By Elizabeth Cooney FDA reverses decades-old warning on hormone therapy products for menopause FDA removes black box warning on hormone therapy, reflecting new science on menopause, heart health, and evolving views on women's care. By Theresa Gaffney and Chelsea Cirruzzo APStock STAT+ | Amgen's cholesterol shot prevented first heart attacks and strokes, more detailed data affirm Amgen's Repatha lowered first heart attacks and strokes by 36% in a major trial, suggesting PCSK9 drugs may prevent acute disease. By Elizabeth Cooney Opinion: It's time to fundamentally rethink how America pays for health care We must change the underlying valuation to reward cognitive health "care" services rather than high-tech "cure" services, doctor writes. By Daniel Plotkin

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser